Biomarkers of PARP inhibitor sensitivity

被引：0
|
作者：
Nicholas C. Turner
Alan Ashworth
机构：
[1] The Institute of Cancer Research,Breakthrough Breast Cancer Research Centre
[2] Royal Marsden Hospital,Breast Unit
来源：
Breast Cancer Research and Treatment | 2011年 / 127卷
关键词：
Homologous Recombination; PARP Inhibitor; Sporadic Breast Cancer; Sporadic Cancer; Stall Replication Fork;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 286
页数：3
相关论文
共 50 条
  • [21] Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib.
    Daemen, A.
    Wolf, D. M.
    Korkola, J. E.
    Griffith, O. L.
    Frankum, J. R.
    Jakkula, L. R.
    Wang, N. J.
    Natrajan, R.
    Reis-Filho, J. S.
    Lord, C. J.
    Ashworth, A.
    Gray, J. W.
    Spellman, P. T.
    van't Veer, L.
    CANCER RESEARCH, 2011, 71
  • [22] Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
    Curtin, Nicola J.
    Drew, Yvette
    Sharma-Saha, Sweta
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (12) : 725 - 726
  • [23] PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
    Froehlich, Lisa Marie
    Villar-Miyar, Ana
    Heintze, Tamara
    Sauer, Birgit
    Schittek, Birgit
    INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (02) : 203 - 210
  • [24] Understanding PARP inhibitor sensitivity: Analyses of the genetic interactions between specific PARP inhibitor targets and DNA double-strand repair pathways
    Ghosh, Rajib
    Roy, Sanchita
    Dantzer, Francoise
    Franco, Sonia
    CANCER RESEARCH, 2015, 75
  • [25] Predictive biomarkers for FAK inhibitor sensitivity in ovarian cancer
    Shapiro, Irina M.
    Vidal, Christian M.
    Kolev, Vihren N.
    Weaver, David T.
    Pachter, Jonathan A.
    CLINICAL CANCER RESEARCH, 2013, 19
  • [26] Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment (vol 11, pg 3837, 2012)
    Oplustilova, Lenka
    Wolanin, Kamila
    Mistrik, Martin
    Korinkova, Gabriela
    Simkova, Dana
    Bouchal, Jan
    Lenobel, Rene
    Bartkova, Jirina
    Lau, Alan
    O'Connor, Mark J.
    Lukas, Jiri
    Bartek, Jiri
    CELL CYCLE, 2013, 12 (12) : 1978 - 1978
  • [27] PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes
    Yu, Tony
    Lok, Benjamin H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024,
  • [28] TRIP13 amplification confers PARP inhibitor resistance and polymerase theta inhibitor sensitivity.
    Patterson-Fortin, Jeffrey
    Zhou, Jia
    D'Andrea, Alan
    CANCER RESEARCH, 2021, 81 (13)
  • [29] DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity
    Stoepker, Chantal
    Faramarz, Atiq
    Rooimans, Martin A.
    van Mil, Saskia E.
    Balk, Jesper A.
    Velleuer, Eunike
    Ameziane, Najim
    te Riele, Hein
    de Winter, Johan P.
    DNA REPAIR, 2015, 26 : 54 - 64
  • [30] A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
    Ceccaldi, Raphael
    O'Connor, Kevin W.
    Mouw, Kent W.
    Li, Adam Y.
    Matulonis, Ursula A.
    D'Andrea, Alan D.
    Konstantinopoulos, Panagiotis A.
    CANCER RESEARCH, 2015, 75 (04) : 628 - 634
12345